Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial

BACKGROUND: A previous Phase I/II study demonstrated that TAS‐102 (trifluridine/tipiracil [FTD/TPI]) plus bevacizumab (Bev) has encouraging efficacy and controllable safety for patients with previously treated metastatic colorectal cancer. Therefore, we designed for assessing the efficacy and safety...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Oki, Eiji, Makiyama, Akitaka, Miyamoto, Yuji, Kotaka, Masahiko, Kawanaka, Hirofumi, Miwa, Keisuke, Kabashima, Akira, Noguchi, Tomohiro, Yuge, Kotaro, Kashiwada, Tomomi, Ando, Koji, Shimokawa, Mototsugu, Saeki, Hiroshi, Akagi, Yoshito, Baba, Hideo, Maehara, Yoshihiko, Mori, Masaki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7877360/
https://ncbi.nlm.nih.gov/pubmed/33249761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3618
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados